Homocysteine

Homocysteine Full Name

Homocysteine

Homocysteine Introduction

Homocysteine is a sulfur-containing amino acid generated during methionine metabolism and serves as a highly informative biomarker of one-carbon metabolism, methylation capacity, and transsulfuration pathway integrity. Although homocysteine itself is not a classical therapeutic target, dysregulated homocysteine metabolism has become a major focus in cardiovascular, neurological, metabolic, and inherited disease research because elevated plasma homocysteine (hyperhomocysteinemia) reflects disruption of multiple interconnected enzymatic pathways rather than a single molecular defect. The enzymes cystathionine β-synthase (CBS), methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR/MS), methionine synthase reductase (MTRR), betaine-homocysteine methyltransferase (BHMT), cystathionine γ-lyase (CGL/CTH), and folate-cycle enzyme MTHFD1 collectively regulate homocysteine clearance through remethylation and transsulfuration. Their coordinated activities depend on adequate folate, vitamin B12, vitamin B6, and betaine availability, making homocysteine metabolism particularly sensitive to both genetic variation and nutritional status. For researchers and drug developers, understanding these interconnected pathways is essential for identifying disease mechanisms, selecting biomarkers, interpreting patient variability, and designing precision therapies targeting metabolic dysfunction rather than simply lowering circulating homocysteine concentrations.

The biological functions of homocysteine extend far beyond its role as a metabolic intermediate. Under physiological conditions, intracellular homocysteine contributes to methionine recycling, S-adenosylmethionine production, DNA and histone methylation, redox regulation, glutathione biosynthesis, and cellular antioxidant defense. When homocysteine accumulates, however, excessive concentrations induce endothelial dysfunction, oxidative stress, mitochondrial impairment, chronic inflammation, protein homocysteinylation, and endoplasmic reticulum stress, ultimately disrupting vascular, neural, and immune homeostasis. CBS functions as the rate-limiting enzyme of the transsulfuration pathway, catalyzing the vitamin B6-dependent conversion of homocysteine to cystathionine, whereas MTHFR maintains methyl donor regeneration by producing 5-methyltetrahydrofolate for MTR-mediated remethylation of homocysteine to methionine. Variants such as the common MTHFR C677T polymorphism reduce enzyme stability and activity, predisposing individuals to mild or moderate hyperhomocysteinemia, particularly under folate-deficient conditions. In inherited homocystinuria, more than 190 pathogenic CBS variants have been identified with well-established genotype-phenotype relationships. Mutations including p.I278T are frequently responsive to pyridoxine therapy, whereas p.G307S, p.R125Q, and p.R266K are generally associated with severe disease and poor vitamin B6 responsiveness. Additional defects involving MTR, MTRR, BHMT, MTHFD1, and CGL further illustrate how disturbances throughout one-carbon metabolism contribute to elevated homocysteine levels, while engineered CGL variants with markedly enhanced homocysteine affinity are emerging as promising enzyme replacement strategies for metabolic correction.

Abnormal homocysteine metabolism has been implicated in an expanding spectrum of human diseases, making this pathway increasingly attractive for biomarker discovery and therapeutic innovation. Persistent hyperhomocysteinemia is strongly associated with atherosclerosis, coronary artery disease, ischemic stroke, venous thrombosis, chronic kidney disease, osteoporosis, cognitive decline, Alzheimer's disease, and pregnancy complications including neural tube defects and recurrent pregnancy loss. In endocrine research, growing evidence also supports a molecular connection between elevated homocysteine and thyroid disorders, where impaired thyroid function may influence folate-dependent remethylation and transsulfuration pathways, further aggravating oxidative stress and vascular injury. Genetic studies have additionally demonstrated that polymorphisms in CBS, MTHFD1, and related folate-metabolism genes can alter homocysteine homeostasis and contribute to congenital heart defect susceptibility in specific populations. The substantial geographic and ethnic diversity observed in pathogenic CBS variants highlights the importance of population-specific genetic screening and individualized metabolic evaluation. Consequently, homocysteine-related research is increasingly shifting from simple biomarker measurement toward integrated precision medicine approaches that combine genomic analysis, nutritional assessment, enzyme-targeted therapies, and pathway-specific interventions to improve diagnosis, risk stratification, and treatment outcomes across cardiovascular, neurological, metabolic, and rare inherited disorders.

Alternate Names for Homocysteine

Homocysteine

• 1.Althubity AA. Homocystinuria: Advances in metabolic and molecular therapies targeting homocysteine pathways (Review). Mol Med Rep. 2026, 33(1):34.
  2.Cui L, et al.; Homocysteine and thyroid diseases. Front Endocrinol (Lausanne). 2025, 16:1572997.